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Background
Increasing evidence suggests that interplay between immune cells and tumor cells exerts 
a major influence on oral tumor development and progression (Sahingur and Yeudall 
2015). Furthermore, recent “Cancer Immunoediting” concept provided insights that 
immune system has both immune surveillance and tumor promotion effects during 
the cancer development (Dunn et al. 2004; Schreiber et al. 2011). In recent years, with 
the rapid development of molecular biology and immunology and the multidisciplinary 
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cross integration, achievements have been made in the research of mutual regulation 
among immunological cells in tumor tissues (de Cos Escuin 2014; Liu et al. 2014). Of 
the examination indexes for diagnosing the development, progression and progno-
sis of tumors, the detection of lymphocyte subgroups in peripheral blood is the most 
popular one in clinic (Liu et al. 2014; Jozwik et al. 2015). It is established that an effec-
tive anti-tumor immune response requires the involvement of both CD4+ and CD8+ T 
cells (Dunn et al. 2004; Schreiber et al. 2011). The role of CD4+ T cells in anti-tumor 
immunity has recently been extensively studied in both pre-clinical animal models and 
clinical cancer patients. CD4+ T cells are critical for priming of tumor-specific CD8+ 
T cells and for the secondary expansion and memory of CD8+ T cells as well (Janssen 
et  al. 2003). The immune status of patients is commonly evaluated in terms of circu-
lating lymphocyte subsets, including CD3+ T cells, CD3+CD4+ T cells, CD3+CD8+ 
T cells, CD19+ B cells and CD56+ NK cells (Plonquet et al. 2007; Ersvaer et al. 2007). 
There are some works on the role of the T cells in head neck squamous cell carcinoma. 
Boucek et al. analyzed the blood samples from 112 patients with head and neck squa-
mous cell carcinoma lymphocyte subpopulations (CD3+; CD3−CD16+CD56+; CD4+; 
CD8+; CD19+; CD4+CD45RA+). The results demonstrated that the percentage of CD8+ 
cells increased and the CD4/CD8 ratio decreased with tumor grade. The ratio of B lym-
phocytes decreased in patients with locoregional metastases (11.25 versus 9.22 %). Treg 
(15.2 %) and CD4+ cells (45.3 %) increased, while NK cells (11.8 %) decreased in HNSCC 
patients compared to controls (9.0, 38.1 and 15.8 %, respectively) (Boucek et al. 2010). 
Starska et al. performed the cytofluorymetric analysis of the early (CD69+, CD71+) and 
late activation markers (CD25+high, CD26
+, HLA/DR+) expression on T CD3+CD4+ and 
CD3+CD8+ cells subpopulations in mixed cellular cultures of freshly isolated tumor 
cells (MLTMC) and non-cancerous normal epithelial cells (MLNCC) in 55 cases of 
squamous cell laryngeal carcinomal. Meanwhile, the whole peripheral blood concentra-
tions of IL-10 and IFN-g in 21 and 72 h of experiments were also measured by ELISA. 
In addition, Starska et al. identified that the expressions of CD69+ and CD71+ antigens 
on T CD3+CD4+ and CD3+CD8+ cells as well as CD4+HLA/DR+ markers were higher 
for pT3 and pT4 tumors, in comparison with pT2 carcinomas. These studies were simi-
lar with our present study (Starska et al. 2011a, b). However, few studies were focused 
on the dynamic correlation between circulating lymphocyte subsets and different treat-
ments in patients with oral squamous cell carcinoma (OSCC). Furthermore, the influ-
ence of chemotherapy (CT) and radical operation on circulating lymphocyte subsets of 
patients with OSCC remains unclear (Lau et al. 2007; Hsu et al. 2010). In the current 
study, the correlations between circulating immune subsets and pre- and post-treatment 
as well as the clinical characteristics were investigated in OSCC patients.
Methods
Patients
The study protocol was approved by the ethical committee of the Sichuan Cancer Hos-
pital, China and was performed in accordance with the ethical standards laid down in 
the 1964 Declaration of Helsinki and its later amendments. The clinical data, including 
age, gender, location, size of tumor, nodal status, histologic type, and treatment were 
obtained in department of Head and Neck Oncology Surgery, Sichuan Cancer Hospital 
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from January 2013 to December 2014. The diagnosis depended on the pathological find-
ing and every case was restaged according to the UICC TNM Classification of Malignant 
Tumors (The seventh edition). All cases were histologically graded into well, intermedi-
ate and poor grade OSCC. The primary locations of tumor were from tongue, buccal, 
and the floor of mouth. The patients with T1/N0 OSCC only received radical operation 
(extensive resection). The patients with T2–4/N1–3 OSCC received 2 cycles TP regime 
chemotherapy and then radical operation, including extensive resection of the primary 
tumor, partial resection of maxillary/mandible, and functional neck dissection (Level 
I–V). The TP chemotherapy regime was comprised 30 mg/m2 cisplatin on days 1–3 plus 
100 mg/m2 paclitaxel on days 1.
Immune subset measurement
Before treatment and 7 days after 2 cycles CT or radical operation, analysis of total lym-
phocytes and subsets was performed on whole blood samples (100 μL; 5 × 105–1 × 106 
cells) collected into EDTA-treated tubes. Blood was stained with the following conju-
gated murine antihuman monoclonal antibodies (Becton–Dickinson, San Jose, CA, 
USA): CD4 (T helper cells), CD8 (cytotoxic T cells), CD19 (B cells) and CD56 (natu-
ral killer cells). The mixtures were incubated for 30 min in the dark, washed with PBS 
(3 mL) and centrifuged at 1500 rpm for 5 min. Cells were analyzed using a multiparamet-
ric four-color flow cytometer (BD FACSCalibur, CA, USA). Percentages of circulating 
CD3+CD4+ T cells, CD3+CD8+ T cells, CD3−CD19+ B cells and CD3−CD16+CD56+ 
NK cells were quantified, and CD4+/CD8+ ratios were also calculated with Cellquest 
software (BD Biosciences).
Statistical analysis
Data are expressed as mean ±  standard deviation (SD). The significance of difference 
between groups was determined by paired or unpaired two-tailed Student’s t test or the 
one-way analysis of Variance (ANOVA). Difference was considered significant for p val-
ues less than 0.05.
Results
The clinical data
Patients’ age ranged from 23 to 77 years (median 58.8), with 21 cases belonging to the 
>60 age group, accounting for 48.8 % of all patients. The locations of primary tumor were 
tongue, buccal, and the floor of mouth, respectively. There were 34 male and 9 female 
subjects. The size of the primary tumor was 1.5–6.0 cm (median 4.5). According to the 
seventh edition of the TNM classification, 17 cases were clinically classified as T1–2 and 
26 cases were clinically classified as T3–4. In addition, 19 cases were clinically classified 
as N0 and 24 cases were clinically classified as N1–3. Only two cases had lung and bone 
metastasis. The primary diagnosis was performed by incisional biopsy. 21 were patho-
logically classified as well differentiated OSCC, 14 cases as intermediate differentiated 
OSCC, and 8 cases as poor differentiated OSCC. Clinical data of all cases are summa-
rized in Table 1.
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Accumulation of CD3+CD4+, CD3+CD8+ T cells, CD3−CD19+ B cells, and CD3−CD56+ NK 
cells subsets in different OSCC development and progression
To better understand the interactions and role of immune system in the pathogenesis 
of OSCC, four lymphocyte subtypes (CD3+CD4+, CD3+CD8+ T cells, CD3−CD19+ 
B cells, and CD3−CD16+CD56+ NK cells) were analyzed from peripheral blood using 
flow cytometer. Firstly, we analyzed the role of different clinical data on four lympho-
cyte subtypes in OSCC. The results demonstrated that there were no differences of lym-
phocyte subtypes change between female and male and among different location. There 
was only significant difference of CD3+CD8+ T cells numbers in 40–60 age group, com-
pared to ≤40 age group and ≥60 age group (P < 0.05) (Fig. 1). Notably, the percentage 
of CD3+CD4+ T cells and CD3+CD8+ T cells distribution was significantly different in 
OSCC patients with different tumor size and nodal status. The percentage of CD3+CD4+ 
T cells distribution was significantly increased in OSCC patients with T3–4 tumor size 
(42.39 ± 5.49), compared to that with T1–2 tumor size (29.06 ± 3.44). The percentage 
of CD3+CD8+ T cells distribution was significantly increased in OSCC patients with 
T3–4 tumor size (30.69 ± 4.08), compared to that with T1–2 tumor size (22.65 ± 3.10). 
The same tendency was also observed in patients with different nodal status. The per-
centage of CD3+CD4+ T cells distribution was significantly increased in OSCC patients 
Table 1 Correlations between the percentage of different lymphocyte subgroups and clin-
icopathologic characteristics in OSCC
a Compared with ≤40 group and ≥60 group, a < 0.05
b Compared with T3–4 group, b < 0.0001
c Compared with T3–4 group, b < 0.0001
d Compared with N1–3 group, b < 0.0001
e Compared with N1–3 group, b < 0.0001
Groups N CD3+CD4+ CD3+CD8+ CD3−CD19+ CD3−CD56+
Gender
 Male 34 37.27 ± 8.29 27.79 ± 5.57 10.24 ± 5.08 18.75 ± 9.00
 Female 9 36.56 ± 7.88 26.44 ± 4.98 10.58 ± 3.76 16.49 ± 8.66
Age
 ≤40 3 30.33 ± 4.04 22.33 ± 3.51 9.50 ± 2.17 24.60 ± 4.85
 40–60 19 39.68 ± 6.95 29.58 ± 4.74a 11.04 ± 5.63 18.48 ± 9.42
 ≥60 21 35.76 ± 8.84 26.38 ± 5.55 9.77 ± 4.29 17.19 ± 8.73
Location
 Tongue 21 38.1 ± 8.09 27.33 ± 5.17 11.03 ± 5.89 19.14 ± 8.97
 Floor of mouth 13 36.69 ± 8.04 27.92 ± 5.82 9.60 ± 3.35 17.06 ± 9.00
 Buccal 9 35.44 ± 8.93 27.33 ± 6.02 9.66 ± 3.85 18.02 ± 9.31
Tumor size
 T1–2 17 29.06 ± 3.44b 22.65 ± 3.10c 1048 ± 4.52 15.82 ± 8.39
 T3–4 26 42.39 ± 5.49 30.69 ± 4.08 10.20 ± 5.06 19.89 ± 8.98
Nodal status
 N0 19 30.58 ± 5.04d 24 ± 4.66e 1045 ± 4.78 17.48 ± 9.34
 N1–3 24 42.29 ± 6.10 30.29 ± 4.30 10.20 ± 4.91 18.91 ± 8.65
Pathological grading
 Well differentiated 21 40.75 ± 7.05 29.52 ± 5.12 10.48 ± 5.58 18.55 ± 8.19
 Intermediate differentiated 14 33.14 ± 6.37 25 ± 4.99 10.03 ± 4.31 19.26 ± 10.39
 Poor differentiated 8 33.75 ± 8.46 26.63 ± 5.42 10.36 ± 3.79 15.85 ± 8.47
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with N1–3 (42.29 ± 6.10), compared to that with N0 (30.58 ± 5.04). The percentage of 
CD3+CD8+ T cells distribution was also significantly increased in OSCC patients with 
N1–3 (30.29 ± 4.30), compared to that with N0 (24 ± 4.66).
Dynamic distributions of CD4+, CD8+ T cells, CD19+ B cells, and CD56+ NK cells subsets 
in patients with different tumor size of OSCC received different treatments
To investigate the dynamic distributions of four lymphocyte subtypes in OSCC with dif-
ferent TNM classification received two-cycle chemotherapy and radical operation, we 
analyzed the percentage of CD3+CD4+, CD3+CD8+ T cells, CD3−CD19+ B cells, and 
CD3−CD16+CD56+ NK cells distribution in different time point, including 3 days before 
treatment, 1 week after 1 cycle chemotherapy, 1 week after 2 cycles chemotherapy, and 
1 week after radical operation. According to UICC TNM classification, we analyzed the 
four lymphocyte subtypes distribution in patients with tumor size (T1–2) in four time 
points, compared to patients with tumor size (T3–4). The result demonstrated that 
there was no difference of CD3+CD4+ T cells distribution in patients with T1–2 tumors 
Fig. 1 Accumulation of lymphocyte subgroups in OSCC patients with different clinical characteristics. a The 
percentage of circulating CD3+CD4+ and CD3+CD8+ T cells, CD3−CD19+ B cells, and CD3−CD16+CD56+ NK 
cells in the OSCC patients with different gender; b the percentage of circulating CD3+CD4+ and CD3+CD8+ 
T cells, CD3−CD19+ B cells, and CD3−CD16+CD56+ NK cells in the OSCC patients with different location of 
primary tumor; c the percentage of circulating CD3+CD4+ and CD3+CD8+ T cells, CD3−CD19+ B cells, and 
CD3−CD16+CD56+ NK cells in the OSCC patients with different age. Error bars indicate mean ± SD, *P < 0.05
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with no treatment in comparison with the 1 week after 1 cycle chemotherapy. But for 
patients with T1–2 tumors received 2 cycles CT and radical operation, the percentage of 
CD3+CD4+ T cells distribution was significantly increased, compared to that with no 
treatment and 1 week after 1 cycle CT (P < 0.0001) (Fig. 2a). Moreover, there was no dif-
ference in patients with no treatment and 1 week after 1 cycle CT, and between 1 week 
after 2 cycles CT and post-operation. For CD3+CD8+ T cells distribution, we observed 
that the T cells distribution was significantly decreased in patients with T1–2 received 
2 cycles CT or radical operation, compared to the patients with T1–2 received no treat-
ment or 1 cycle CT (P < 0.0001). Interestingly, CD3+CD8+ T cells seems to be increased 
in patients with T1–2 received 1 cycle CT, compared to that received no treatment 
(Fig. 2b). We also analyzed the CD3−CD19+ B cells and CD3−CD16+CD56+ NK cells 
distribution in different time points for these patients. The CD3−CD19+ B cells distri-
bution only increased in patients with T1–2 received radical operation, compared to the 
time point of no treatment or 1–2 cycles CT (p < 0.0001) (Fig. 2c). There seems to be no 
difference for CD3−CD16+CD56+ NK cells distribution in all four time points (Fig. 2d). 
Almost the same tendency was observed in OSCC patients with T3–4 tumor size. For 
patients with T3–4 tumors received 2 cycles CT and radical operation, the percentage of 
CD3+CD4+ T cells distribution was significantly increased, compared to the time points 
of no treatment and 1 cycle CT (P < 0.0001) (Fig. 2e). Two-cycles CT and radical opera-
tion significantly decreased the percentage of CD3+CD8+ T cells, compared to the time 
points of no treatment or 1 cycle CT (p < 0.0001) (Fig. 2f ). The radical operation is the 
only time point to increase the distribution of CD3−CD19+ B cells in comparison with 
the other three time points (p < 0.05) (Fig. 2g). The distribution of CD3−CD16+CD56+ 
NK cells was still no change in all four time points (Fig. 2h).
Dynamic distributions of CD4+, CD8+ T cells, CD19+ B cells, and CD56+ NK cells subsets 
in patients with different nodal status of OSCC received different treatments
To evaluate the role of nodal status on lymphocyte subtypes distribution in OSCC 
patients received different treatments, we also analyzed the percentage of CD4+, CD8+ 
T cells, CD19+ B cells, and CD56+ NK cells distribution using flow cytometer. Similarly, 
the percentage of CD3+CD4+ T cells distribution was significantly increased in OSCC 
patients received 2 cycles CT and radical operation, compared to that received no treat-
ment and 1 cycle CT (P  <  0.0001) (Fig.  3a). There were also no differences between 
the patients received no treatment and 1 cycle CT, and between the patients received 
2 cycles CT and radical operation. The percentage of CD3+CD8+ T cells distribution 
(see figure on next page.)  
Fig. 2 The accumulation of lymphocyte subgroups in OSCC patients with different tumor size received differ-
ent treatments. a The accumulation of CD3+CD4+ T cells in the OSCC patients with T1–2 size of primary tumor 
received different treatments; b the accumulation of CD3+CD8+ T cells in the OSCC patients with T1–2 size of 
primary tumor received different treatments; c the accumulation of CD3−CD19+ B cells in the OSCC patients 
with T1–2 size of primary tumor received different treatments; d the accumulation of CD3
−CD16+ CD56+ NK 
cells in the OSCC patients with T1-2size of primary tumor received different treatments; e the accumulation 
of CD3+CD4+ T cells in the OSCC patients with T1–2 size of primary tumor received different treatments; f the 
accumulation of CD3+CD8+ T cells in the OSCC patients with T3–4 size of primary tumor received different 
treatments; g the accumulation of CD3−CD19+ T cells in the OSCC patients with T3–4 size of primary tumor 
received different treatments; h the accumulation of CD3−CD16+ CD56+ NK cells in the OSCC patients with 
T3–4 size of primary tumor received different treatments. Error bars indicate mean ± SD, *P < 0.05, **P < 0.0001
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significantly decreased in OSCC patients with no lymph nodes metastasis received 2 
cycles CT and radical operation, compared to that received no treatment and 1 cycle 
CT (Fig.  3b). The OSCC patients with no lymph nodes metastasis demonstrated that 
the CD3−CD19+ B cells distribution significantly increased in time point of post-oper-
ation, compared to the other three time points (p  <  0.0001) (Fig.  3c). There was also 
no difference distribution of CD3−CD16+CD56+ NK cells among four time points in 
OSCC patients with no lymph nodes metastasis (Fig. 3d). We also analyzed the percent-
age of four lymphocyte subtypes distribution in OSCC patients with N1–3 lymph nodes 
metastasis received different treatments. The results demonstrated that the CD3+CD4+ 
T cells distribution was significantly increased in patients with N1–3 received 2 cycles 
CT and radical operation, compared to that received no treatment and 1 cycle CT 
(p  <  0.0001) (Fig.  3e). Interestingly, after 1 cycle CT, the CD3+CD4+ T cells distribu-
tion was significantly decreased in the patients with N2–3, compared to that received no 
treatment. The percentage of CD3+CD8+ T cells distribution significantly decreased in 
patients with N1–3 received 2 cycles CT and radical operation (Fig. 3f ). We also analyzed 
the CD3−CD19+ B cells and CD3−CD16+CD56+ NK cells distribution in different time 
points for these patients. The CD3−CD19+ B cells distribution significantly increased 
in patients with N1–3 received radical operation, compared to that received 2 cycles CT 
(P < 0.05), 1 cycle CT (p < 0.0001), and no treatment (p < 0.0001) (Fig. 3g). There was no 
difference for CD3−CD16+CD56+ NK cells distribution in patients with N1-3 in all four 
time points (Fig. 3h).
Dynamic distributions of CD4+, CD8+ T cells, CD19+ B cells, and CD56+ NK cells subsets 
in patients with different pathologic grading of OSCC received different treatments
Then we analyzed the percentage of CD4+, CD8+ T cells, CD19+ B cells, and CD56+ 
NK cells distribution using flow cytometer in OSCC patients with different pathological 
grading. For patients with well differentiated tumors, the percentage of CD3+CD4+ T 
cells distribution was significantly increased for patients received 2 cycles CT and radi-
cal operation, compared to the that received no treatment and 1 cycle CT (P < 0.0001, 
p  <  0.05, respectively) (Fig.  4a). Two-cycle CT and radical operation significantly 
decreased the percentage of CD3+CD8+ T cells, compared to the time points of no treat-
ment or 1 cycle CT (p < 0.0001) (Fig. 4b). The radical operation is the only time point to 
increase the distribution of CD3−CD19+ B cells in comparison with the other three time 
points (p < 0.0001) (Fig. 4c). The distribution of CD3−CD16+CD56+ NK cells was still no 
change in all four time points (Fig. 4d). The same tendency was observed in CD3+CD4+ 
(see figure on next page.)  
Fig. 3 The accumulation of lymphocyte subgroups in OSCC patients with different nodal status received 
different treatments. a The accumulation of CD3+CD4+ T cells in the OSCC patients with N0 received different 
treatments; b the accumulation of CD3+CD8+ T cells in the OSCC patients with N0 received different treat-
ments; c the accumulation of CD3−CD19+ B cells in the OSCC patients with N0 received different treatments; 
d the accumulation of CD3−CD16+ CD56+ NK cells in the OSCC patients with N0 received different treat-
ments; e the accumulation of CD3+CD4+ T cells in the OSCC patients with N1–3 received different treatments; 
f the accumulation of CD3+CD8+ T cells in the OSCC patients with N1–3 received different treatments; g the 
accumulation of CD3−CD19+ T cells in the OSCC patients with N1–3 received different treatments; h the accu-
mulation of CD3−CD16+ CD56+ NK cells in the OSCC patients with N1–3 received different treatments. Error 
bars indicate mean ± SD, *P < 0.05, **P < 0.0001
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T cells distribution in these patients received different treatments as those patients with 
intermediate differentiated tumors (Fig. 4e). Moreover, two-cycle CT and radical opera-
tion significantly decreased the percentage of CD3+CD8+ T cells, compared to the time 
points of no treatment or 1 cycle CT (p  <  0.0001). However, 1 cycle CT seems to be 
increased the percentage of CD3+CD8+ T cells, compared to the patients received no 
treatment (Fig.  4f ). There was significant difference of CD3−CD19+ B cells between 
patients with intermediate differentiated tumors received radical operation and that 
received no treatment, and between patients with intermediate differentiated tumors 
received radical operation and that received 1 cycle CT (Fig.  4g). The distribution of 
CD3−CD16+CD56+ NK cells was still no change in all four time points (Fig. 4h). At last, 
we analyzed that the CD4+, CD8+ T cells, CD19+ B cells, and CD56+ NK cells distribu-
tion using flow cytometer in OSCC patients with poor differentiated tumors received 
different treatments. The percentage of CD3+CD4+ T cells distribution was significantly 
increased in patients received 1cycle CT, 2 cycles CT and radical operation, compared 
to the time points of no treatment (P < 0.0001) (Fig. 4i). The percentage of CD3+CD8+ 
T cells distribution was also significantly decreased in patients with poor differentiated 
tumors received 1 cycle CT (p < 0.0001), 2 cycles CT (p < 0.05), and radical operation 
(p  <  0.0001), compared to that patients received no treatment. Moreover, the radical 
operation significantly increased the distribution of CD3−CD19+ B cells in patients 
with poor differentiated tumors, compared to that received no treatment and 1 cycle CT 
(Fig. 4j). However, 2 cycles CT seems to be decreased the distribution of CD3−CD19+ B 
cells in patients with poor differentiated tumors, compared to that received 1 cycle CT 
and radical operation (Fig. 4k). The distribution of CD3−CD16+CD56+ NK cells was still 
no change in all four time points (Fig. 4l).
Association of CD4+/CD8+ ratio with OSCC patients received different treatments
To evaluate the effect of different treatments on patients with OSCC, we also analyze 
the CD4+/CD8+ ratio in all OSCC patients received no treatment, 1 cycle CT, 2 cycles 
CT, and radical operation. The 2 cycles CT and radical operation indeed increased 
the CD4+/CD8+ ratio in OSCC patients, compared to that received no treatment or 1 
cycle CT (P < 0.0001). There was no significant difference between patients received no 
treatment and patients received 1 cycle CT, between patients received 2 cycles CT and 
patients received radical operation (Fig. 5). These data suggested that the 2 cycles CT 
and radical operation treatment may be essential to increase the effect of treatment for 
the patients with OSCC.
Discussion
Kuhn et al. reported that abnormal T lymphocyte subgroups were found in peripheral 
blood, marked by decreased CD3+CD4+ expression and increased CD3+CD8+ expres-
sion (Kuhn et  al. 2013). However, comprehensive understanding of the role of CD4+ 
T cells in anti-tumor immunity is challenging in tumor immunology research and the 
results have been controversial. Besides the traditional functions of Th1 and Th2 cells in 
helping tumor-specific CD8+ T cells and B cells, recent discovery of Th17 and Treg cells 
has not only resulted in an explosion of cancer immunological research but also mark-
edly changed our conventional thinking of the role of CD4+ T cells in the pathologenesis 
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Fig. 4 The accumulation of lymphocyte subgroups in OSCC patients with different pathological grad-
ing received different treatments. a the accumulation of CD3+CD4+ T cells in the OSCC patients with well 
differentiated tumors received different treatments; b the accumulation of CD3+CD8+ T cells in the OSCC 
patients with well differentiated tumors received different treatments; c the accumulation of CD3−CD19+ 
B cells in the OSCC patients with well differentiated tumors received different treatments; d the accumula-
tion of CD3−CD16+ CD56+ NK cells in the OSCC patients with well differentiated tumors received different 
treatments; e the accumulation of CD3+CD4+ T cells in the OSCC patients with intermediate differentiated 
tumors received different treatments; f the accumulation of CD3+CD8+ T cells in the OSCC patients with 
intermediate differentiated tumors received different treatments; g the accumulation of CD3−CD19+ T cells 
in the OSCC patients with intermediate differentiated tumors received different treatments; h the accumula-
tion of CD3−CD16+ CD56+ NK cells in the OSCC patients with intermediate differentiated tumors received 
different treatments. i the accumulation of CD3+CD4+ T cells in the OSCC patients with poor differentiated 
tumors received different treatments; j the accumulation of CD3+CD8+ T cells in the OSCC patients with poor 
differentiated tumors received different treatments; k the accumulation of CD3−CD19+ T cells in the OSCC 
patients with poor differentiated tumors received different treatments; l the accumulation of CD3−CD16+ 
CD56+ NK cells in the OSCC patients with poor differentiated tumors received different treatments. Error bars 
indicate mean ± SD, *P < 0.05, **P < 0.0001
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of cancer development. In this study, OSCC patients in advanced group (T3–4/N1–3) was 
significantly higher in expression of CD3+CD4+ cells in peripheral blood than early 
group (T1–2/N0). It’s reported that in early tumor stages, Th1 cells are the dominant 
population of CD4+ T cells, perhaps important for immunosurveillance; while in the 
advanced tumor stages, FoxP3+ Treg and Th17 cells become the dominant populations. 
It is well recognized that tumor-infiltrating Treg cells are a major obstacle for the success 
of tumor immunity and immunotherapy (Curiel 2008; Perez et al. 2007; Peng et al. 2007). 
Huang et al. also reported that the intra-tumoral CD4+ T cells numbers were positively 
correlated with advanced tumor stage, large tumor size, and positive tumor metastasis, 
but were inversely correlated with survival of breast cancer patients (Huang et al. 2015). 
Therefore, this study maybe suggested that in the late tumor stage, CD4+ T cells become 
more important for promoting tumor growth. The expression of CD3+CD8+ seemed 
to be decreased in early group (T1–2/N0), compared to that in advanced group (T3–4/
N1–3). However, except for group between ≤40 age group and ≥60 age group in com-
parison with 40–60 age group, there were no significant differences in the expression 
of CD3+CD4+ and CD3+CD8+ in OSCC patients with different pathological patterns, 
genders, and locations.
Accumulating research findings suggested that there are multiple antitumor T cell 
clones in the peripheral blood of patients with lymphoma, but these T lymphocytes fail 
to retain effective antitumor properties (Yin et  al. 2010, 2011). Interestingly, Yin et  al. 
showed that imbalance T-lymphocyte subsets occurs in patients with lymphoma dur-
ing different chemotherapy stages, and these T-lymphocyte subsets gradually return to 
normal by 3 months after chemotherapy (Yin et al. 2014). Given the poor prognosis of 
OSCC, the patients with OSCC (T2–4/N1–3) received 2 cycles TP regime chemother-
apy and radical operation, including extensive resection of the primary tumor, partial 
Fig. 5 The CD4+/CD8+ ratio in OSCC patients received different treatments. Error bars indicate mean ± SD, 
**P < 0.0001
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resection of maxillary/mandible, and functional neck dissection (Level I–V). To evalu-
ate the dynamic effect of chemotherapy or operation on patients with OSCC, the lym-
phocytes subgroups were analyzed using flow cytometer. Interesting, 2 cycles TP regime 
chemotherapy and radical operation indeed significantly increased the expression of 
CD3+CD4+ T cells and decreased the expression of CD3+CD8+ T cells in almost all 
OSCC patients. The results suggested that the 2 cycles CT and radical operation were 
essential to improve the prognosis of OSCC patients. It is suggested that CD4+/CD8+ 
ratio is crucial to be kept in a dynamic balance, in terms of maintaining the immuno-
logical function stable (Dou et  al. 2013). The ratio decreased is reported to link with 
a low immunological function (Erdem et  al. 2012; Nugroho et  al. 2012). In this study, 
The patients with OSCC received 2 cycles CT or radical operation had a significantly 
higher level of CD4+/CD8+ ratio compared with that received no treatment or 1 cycle 
CT. NK cell is also designated as natural killer cells. NK cell could directly destroy 
tumor cells, and reduced level of NK cell will lead to decline of immunological func-
tion (Wang et al. 2013). Our results showed that there is no difference of expression of 
CD3–CD16+CD56+ NK cell in OSCC patients received different treatments, suggest-
ing no significant influence of different treatments of NK cells on patients with OSCC. 
The CD19 molecule is a phenotypic marker of B cells. In EBV-associated disease, B cells 
are the principal targets of viral infection and play a significant role in the anti-tumor 
humoral responses by differentiating into antibody producing plasma B cells. The prog-
nostic value of CD19+ B cells also has been observed in breast cancer and acute myeloid 
leukemia (Tredan et  al. 2013; Iriyama et  al. 2013). The high percentage of circulating 
CD19+ B cells alone correlated positively with better PFS of nasopharyngeal carcinoma 
(Xu et al. 2014). In our study, the expression of CD19+ B cells were only increased in 
OSCC patients received radical operation with different T stage, nodal status and patho-
logical grading. There is no relationship between 2 cycles TP regime chemotherapy and 
the expression of CD19+ B cells. The mechanism need to be further explored.
Conclusion
In this study, the expression of CD4+ T cells were significantly increased in advanced 
tumor stage, large tumor size and positive lymph nodes metastasis, compared to that in 
early group. 2 cycles TP regime chemotherapy and radical therapy may be essential to 
increase the effects of anti-tumor immunity on patients with OSCC. However, the posi-
tive correlation between circulating CD19+ B cells and radical operation in patients with 
OSCC still need to be further explored in future study. The analysis of lymphocyte sub-
groups in peripheral blood detected by flow cytometry suggested that the lymphocyte 
subgroups may be the prognostic factor of OSCC.
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